Floatz logo

Cyclophosphamide

Mycosis Fungoides/Sezary Syndrome

University of Michigan Rogel Cancer CenterSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Mycosis Fungoides/Sezary Syndrome cohort.

Asset / SponsorPhaseRating
Epirubicin
University of Michigan Rogel Cancer Center
Phase 2BB
Pembrolizumab
University of Michigan Rogel Cancer Center
Phase 2BB
Lacutamab
Innate Pharma
Phase 2B
Atezolizumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2CCC
Tazemetostat
Washington University School of Medicine
Phase 2CCC
VITPSO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2CCC
Cefepime
Wake Forest University Health Sciences
Phase 1CC
Tulmimetostat
Washington University School of Medicine
Phase 1CC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →